FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Para fines de investigación únicamente. Aviso completo →

Biblioteca de Peptidos

NAD+

Nicotinamide Adenine Dinucleotide / NAD

Longevity & Anti-Aging

NAD+ (nicotinamide adenine dinucleotide) is a critical coenzyme present in every living cell, functioning as an essential electron carrier in mitochondrial energy production and as a substrate for sirtuins, PARPs, and CD38 enzymes involved in DNA repair and cellular signaling. Declining NAD+ levels are strongly associated with aging and metabolic dysfunction, making NAD+ repletion a major focus of longevity research. It is administered via IV infusion, subcutaneous injection, or oral precursors (NMN, NR) in anti-aging and neurological research protocols.

Mecanismo de Acción

Essential coenzyme present in all living cells. Central to cellular energy metabolism (glycolysis, TCA cycle, oxidative phosphorylation), DNA repair (PARP enzymes), epigenetic regulation (sirtuins), and calcium signaling. Levels decline ~50% between ages 40-60.

Protocolos de Investigación

Para propósitos de investigación solo. No es asesoramiento médico.

Research protocols use 250-750mg via IV infusion over 2-4 hours. Subcutaneous protocols use 50-100mg daily. Intranasal formulations under investigation. IV sessions typically weekly for 4-8 weeks, then monthly maintenance.

Notas de Investigación

Clinical Research Status

NAD+ IV therapy is actively studied in clinical trials for conditions including chronic fatigue, neurodegenerative diseases, substance use disorders, and age-related metabolic decline. The precursors NMN and NR have multiple ongoing Phase I/II trials examining bioavailability, safety, and effects on aging biomarkers. While IV NAD+ clinics have proliferated globally, FDA-approved therapeutic indications remain limited to experimental and integrative medicine settings.

Key Published Findings

Research has demonstrated that NAD+ levels decline by approximately 50% between ages 40 and 60, correlating with mitochondrial dysfunction and increased disease susceptibility. Studies in animal models show that NAD+ repletion restores mitochondrial function, improves insulin sensitivity, and extends healthspan markers. Human trials with NR supplementation have confirmed dose-dependent increases in blood NAD+ levels with good tolerability, though functional clinical endpoints are still being validated.

Safety Profile

IV NAD+ infusions are generally well-tolerated but commonly produce transient side effects including chest tightness, nausea, abdominal cramping, and flushing during infusion, which are managed by slowing the drip rate. Oral precursors NMN and NR show excellent safety profiles in clinical doses of 250-1000mg daily with minimal adverse events reported. Theoretical concerns exist about long-term high-dose NAD+ supplementation potentially fueling growth of existing cancers, though clinical evidence for this remains inconclusive.

Drug Interactions & Contraindications

NAD+ may interact with blood pressure medications due to its vasodilatory effects during IV administration. Caution is advised with concurrent use of chemotherapeutic agents, as NAD+-dependent PARP inhibitors may have altered efficacy. Patients with active malignancies should consult their oncologist before beginning NAD+ therapy given the theoretical role of NAD+ in supporting cellular proliferation.

Comparison to Related Compounds

NMN (nicotinamide mononucleotide) is a direct NAD+ precursor requiring one enzymatic step for conversion, offering potentially faster NAD+ elevation than NR. NR (nicotinamide riboside) has more published human clinical trial data and established commercial availability as a supplement (TruNiagen, Elysium). Direct IV NAD+ bypasses the need for enzymatic conversion entirely but requires clinical administration and produces more acute side effects than oral precursors.

Community Observations

Users of IV NAD+ commonly report initial sessions being uncomfortable due to nausea and chest tightness, with subsequent sessions becoming more tolerable as the body adapts. Many practitioners administer loading protocols of 500-1000mg IV daily for 3-5 days followed by monthly maintenance infusions. The biohacking community frequently combines NAD+ protocols with resveratrol and fasting to maximize sirtuin activation and perceived anti-aging benefits.

Media Vida

~45 minutes (IV)

Reconstitución

Sterile saline for IV; bacteriostatic water for SubQ

Almacenamiento

Liofilizado

Refrigerate 2-8C. Protect from light.

Reconstituído

Use within 24 hours of preparation (IV). SubQ: within 7 days.

Estado Legal EE.UU.

Supplement (not FDA-regulated as drug)

También Se Conoce Como

Nicotinamide Adenine DinucleotideNAD

Preguntas frecuentes

¿Qué es NAD+?

NAD+ (nicotinamide adenine dinucleotide) is a critical coenzyme present in every living cell, functioning as an essential electron carrier in mitochondrial energy production and as a substrate for sirtuins, PARPs, and CD38 enzymes involved in DNA repair and cellular signaling. Declining NAD+ levels are strongly associated with aging and metabolic dysfunction, making NAD+ repletion a major focus of longevity research. It is administered via IV infusion, subcutaneous injection, or oral precursors (NMN, NR) in anti-aging and neurological research protocols.

¿Cómo funciona NAD+?

Essential coenzyme present in all living cells. Central to cellular energy metabolism (glycolysis, TCA cycle, oxidative phosphorylation), DNA repair (PARP enzymes), epigenetic regulation (sirtuins), and calcium signaling. Levels decline ~50% between ages 40-60.

¿Cuál es el estado regulatorio de NAD+ en EE. UU.?

Supplement (not FDA-regulated as drug)

¿Cuál es la vida media de NAD+?

~45 minutes (IV)

¿Qué otros nombres tiene NAD+?

Nicotinamide Adenine Dinucleotide, NAD

Peptide Contacts proporciona resúmenes basados en investigaciones únicamente para fines informativos. No hospedamos, distribuimos ni endosamos la documentación del proveedor. Todos los certificados de análisis, certificados GMP y comunicaciones del proveedor deben solicitarse y verificar directamente por el comprador. Nada en esta plataforma constituye asesoramiento legal, médico o profesional. Los usuarios son únicamente responsables de verificar las credenciales del proveedor y asegurarse de cumplir con todas las leyes locales, estatales y federales aplicables antes de comprar cualquier químico de investigación. El uso de esta plataforma constituye aceptación de toda la responsabilidad personal.

Leer aviso completo